Generic Nucynta Availability

See also: Generic Nucynta ER

Nucynta is a brand name of tapentadol, approved by the FDA in the following formulation(s):

NUCYNTA (tapentadol hydrochloride - solution;oral)

  • Manufacturer: JANSSEN PHARMS
    Approval date: October 15, 2012
    Strength(s): EQ 20MG BASE/ML [RLD]

NUCYNTA (tapentadol hydrochloride - tablet;oral)

  • Manufacturer: JANSSEN PHARMS
    Approval date: November 20, 2008
    Strength(s): EQ 50MG BASE, EQ 75MG BASE, EQ 100MG BASE [RLD]

Has a generic version of Nucynta been approved?

No. There is currently no therapeutically equivalent version of Nucynta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nucynta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
    Patent 6,071,970
    Issued: June 6, 2000
    Inventor(s): Mueller; Alan L. & Balandrin; Manuel F. & VanWagenen; Bradford C. & DelMar; Eric G. & Moe; Scott T. & Artman; Linda D. & Barmore; Robert M.
    Assignee(s): NPS Pharmaceuticals, Inc.
    Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
    Patent expiration dates:
    • June 6, 2017
      ✓ 
      Patent use: RELIEF OF MODERATE TO SEVERE ACUTE PAIN
    • June 6, 2017
      ✓ 
      Patent use: MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
  • Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
    Patent 7,994,364
    Issued: August 9, 2011
    Inventor(s): Fischer; Andreas & Buschmann; Helmut & Gruss; Michael & Lischke; Dagmar
    Assignee(s): Gruenenthal GmbH
    A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
    Patent expiration dates:
    • June 27, 2025
      ✓ 
      Patent use: RELIEF OF MODERATE TO SEVERE ACUTE PAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • June 27, 2025
      ✓ 
      Patent use: MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
    Patent RE39593
    Issued: April 24, 2007
    Inventor(s): Buschmann; Helmut & Strassburger; Wolfgang & Friderichs; Elmar
    Assignee(s): Gruenenthal GmbH
    1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.
    Patent expiration dates:
    • August 5, 2022
      ✓ 
      Patent use: RELIEF OF MODERATE TO SEVERE ACUTE PAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • August 5, 2022
      ✓ 
      Patent use: MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • November 20, 2013 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)